Biotechnology - Rare diseases, Biogen Idec, Nephrology and Hepatology

Biogen Idec files for US approval of long-acting hemophilia A treatment

13-03-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) says it has submitted a Biologics License Application (BLA)…

Biogen IdecBiotechnologyNorth AmericaRare diseasesRegulationrFVIIIFc

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent

27-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced…

Biogen IdecBiotechnologyEuropeNorth AmericaPharmaceuticalRare diseasesRegulationResearchrFIXFcSobiSwedish Orphan Biovitrum

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy

02-07-2012

In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Isis Pharma could earn $299 million from Biogen Idec deal

05-01-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Biogen Idec in up to $553 million deal with Portola for oral Syk inhibitor program

28-10-2011

USA-based Biogen Idec (Nasdaq: BIIB) and Portola Pharmaceutical have entered into an exclusive, worldwide…

Anti-Arthritics/RheumaticsBiogen IdecBiotechnologyLicensingPharmaceuticalPortola PharmaceuticalsRare diseasesResearch

Back to top